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Abstract: With the advent of high-throughput sequencing techniques, the astonishing extent and 
complexity of the microbial communities that reside within and upon us has begun to become clear. 
Moreover, with advances in computing and modelling methods, we are now beginning to grasp 
just how dynamic our interactions with these communities are. The diversity of both these 
communities and their interactions—both within the community and with us—are dependent on a 
multitude of factors, both microbial- and host-mediated. Importantly, it is becoming clear that shifts 
in the makeup of these communities, or their responses, are linked to different disease states. 
Although much of the work to define these interactions and links has been investigating bacterial 
communities, recently there has been significant growth in the body of knowledge, indicating that 
shifts in the host fungal communities (mycobiome) are also intimately linked to disease status. In 
this review, we will explore these associations, along with the interactions between fungal 
communities and their human and microbial habitat, and discuss the future applications of systems 
biology in determining their role in disease status. 
Keywords: mycobiome; microbiome; bacterial-fungal interactions; fungal-fungal interactions; host-
fungal interactions; systems biology 
 
1. Introduction 
With the global burden of fungal diseases rising, researchers have begun to turn to next-
generation sequencing (NGS) technology to investigate the role fungi play in the spectrum of human 
health and disease. At the forefront of this advancement is the “Superorganism” hypothesis, where 
humans are considered to be complex organisms made up of numerous mutually independent 
smaller organisms (i.e., bacteria, fungi, virus, archaea) and their genomes. This group of microbial 
cells and their genomes are collectively referred to as the human microbiota and microbiome, 
respectively. Over the past decade, the bacterial portion of the microbiome has been well 
characterized in a number of health and disease states of man, including: Type 2 diabetes [1–3]; liver 
cirrhosis [4]; colon cancer [5]; rheumatoid arthritis [6], and; inflammatory bowel disease [7–9]. In 
contrast, however, research into the mycobiome (the fungal proportion of the microbiome) has 
received less attention, such that the field of mycobiome research is still in its infancy.  
There are currently several common challenges facing microbiome and mycobiome researchers. 
First, irrespective of their biomass, fungi account for a relatively small percentage of the human 
microbiome compared to their bacterial counterparts [10,11]. Second, similar to what we have seen 
with bacteria, the isolation of nucleic acids from fungal cells can be problematic, and often requires a 
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combination of enzymatic, chemical and mechanical lysis steps [12]. Third, the ability to discriminate 
between fungal taxa is influenced by sequencing primer choice and, finally, curated databases for 
taxonomic assignment and/or the annotation of fungal genomes are lacking or are incomplete [13,14]. 
It is against this backdrop that a number of authors have begun to unravel the mystery of the human 
mycobiome.  
Akin to the microbiome, the human mycobiome has been shown to play an integral role in the 
pathology of health and disease in man [15]. In fact, changes to the mycobiome have been shown to 
play vital roles in the modulation of the host immune response [16,17], disease progression [16], the 
maintenance of microbial population structures [18], as well as metabolic functioning of the host [18].  
This review aims to explore the current status of human mucosal mycobiome research, focusing 
on the gastrointestinal tract. 
2. The Mycobiome 
2.1. Studying the Mycobiome 
The advancements we have seen in high-throughput NGS technology over the past decade, has 
dramatically changed the landscape against which we study the mycobiome. From traditional, 
culture-based methodologies, we have moved towards the use of amplicon based technologies that 
target fungal specific house-keeping genes, which allow researchers to identify both cultivatable and 
non-cultivatable fungal species in a wealth of environmental samples. Theses fungal house-keeping 
genes are situated within the fungal ribosomal RNA gene cluster (rRNA), and include the 18S rRNA, 
5.8S rRNA and 28S rRNA genes, as well as the internal transcribed spacer regions (ITS1 and ITS2) 
[19]. Similar to what has been seen with the 16S rRNA gene in amplicon-based bacterial microbiome 
studies [20], there is currently a lack of consensus between authors regarding which genetic target 
offers the best level of taxonomical and phylogenetic resolution [13], and as such several alternative 
primer sets exists that target different regions of these fungal genes (Cui et al. [19] gives a good 
overview of the different fungal rDNA primers used in mycobiome studies to date). Confounding 
this issue in mycobiome studies is the lack of completely sequenced and annotated fungal genomes 
that can be used for taxonomic identification. Current fungal rRNA databases routinely used to 
assign fungal taxonomy in microbiome studies include UNITE [21] for ITS, SILVA [22] for fungal 18S 
and 28S rRNA genes, as well as RDP [23] for fungal 28S rRNA genes.  
Unlike the field of microbiome research, mycobiome studies tend not to use shotgun 
metagenomic sequencing approaches. As metagenomic approaches simultaneous sequence all of the 
genetic material within a sample (host, bacterial, fungal, archael, etc.), they have the potential to 
generate both taxaonomic and functional information. However, this technique relies on a lot of 
computational power and is limited by the inclusion of both bacterial, fungal and archael genes in 
reference catalogs [24]. In fact, in a current metagenomic reference catalog used for studying gut 
microbial populations [24,25], only 0.1% of the 3.3 million reference genes were reported to be of 
eukaryotic origin [24]. Until we overcome the limitation posed by a lack of fungal reference genes in 
these catalogs, the true potential of mycobiome research using metagenomic approaches cannot be 
fully realized. 
2.2. Mucosal Mycobiomes in Health and Disease 
There is mounting evidence linking the host’s mucosal microbiomes to the modulation of host 
immunity. One’s ability to untangle the complex interactions between the microbiota, mycobiota and 
immune response at a given body site begins with developing an understanding of which microbes 
frequently call these mucosal niches home. A summary of our current knowledge of the mycobiota 
and microbiota that colonize the oral cavity and the lower gastrointestinal tract (GIT) in states of 
health is given in Figure 1. 
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Figure 1. Healthy microbial communities of the human body. An overview of the Mycobiota (a) and 
Microbiota (b) identified on the mucosal surfaces of the oral cavity and lower gastrointestinal tract in 
a state of health. Pie charts depict the average relative abundance of fungal taxa (a); and bacterial taxa 
(b) observed in the healthy oral cavity [26], and gastrointestinal tract [27] of study participants. 
2.2.1. The Oral Mycobiome 
The concept of a “core healthy oral mycobiome” was introduced in 2010 by Ghannoum and 
colleagues when they characterized the oral mycobiome of 20 healthy adults [28]. In this study 
interrogation of ITS1F/ITS2 sequences identified a total of 85 fungal genera within the oral cavity, 11 
of which related to non-culturable fungal genera [28]. Although the exact number of fungal genera 
in the oral cavity varied between participants (range 5–39), a core set of genera were identified in the 
oral cavities of more than 20 percent of study participants: Candida (75%); Cladiosporium (60%); 
Aureobasidium (50%); Aspergillus (35%); Fusarim (30%), and; Cryptococcus (20%). The high prevalence 
of Candida in the oral cavity is consistent with previous culture-based studies, and subsequent 
molecular studies confirmed the high prevalence of Candida spp. within the oral cavity, reporting 
Candida albicans, Candida parapsilosis and Candida dubliniensis as the most abundant oral Candida 
species [26,29,30]. 
The constituents of the “core healthy oral mycobiome” were refined in 2014, when Dupuy and 
colleagues identified only eight of the key oral mycobiome genera originally classified by Ghannoum 
et al. in their healthy saliva samples [29]. This highlights that although a healthy core oral mycobiome 
may exist, the overall abundance and diversity of fungal taxa may be somewhat individualised. One 
of the most interesting aspects of this study was the report of a relative high abundance (13–96%) of 
Malassezia within the oral cavity of their entire study cohort, which is in contrast to previous studies 
which failed to identify Malassezia spp. at all [28,29]. Although, subsequent molecular studies are yet 
to confirm the reports of Malassezia within the oral cavity of man, its presence can be logically 
explained. First, Malassezia is a common skin commensal that has been isolated from the nares [31] 
and respiratory tract [32] of man, thus its presence in the oral cavity is not unexpected. Secondly, as 
Malassezia has a relatively robust cell wall structure, the choice of cell lysis methodology may 
significantly affect the ability to isolate Malassezia DNA, resulting in a subsequent underestimation 
of fungal abundance [12,29]. In light of this, it is important to consider here the differences in the 
DNA extraction processes used in the two studies. In fact, both studies used the same FAST DNA 
Spin Kit for DNA isolation, however, Dupuy et al. modified the protocol to include a robust mix of 
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ceramic and zirconia beads to facilitate mechanical digestion, and also tripled the timing at the 
homogenization step [29]. 
The importance of bacterial-fungal, and fungal-fungal interactions in the homeostatsis of oral 
health, was recently highlighted in individuals with and without HIV [26]. In this study, the authors 
concurrently profiled the microbiome and mycobiome in the oral cavity (Figure 1) of 24 subjects and 
identify a number of significant fungal-fungal correlations in individuals with and without HIV. 
Although both Candida and Penicillium were isolated from the oral cavity of all individuals, significant 
differences in the overall mycobiome profiles were identified between the health and disease states 
[26]. For example, Alternia, Epicoccum and Trichosporon were only found in HIV positive patients, 
whilst Pichia, Cladosporium and Fusarium were associated with health. In contrast, assessments of the 
microbial populations, identified a stable oral microbiome between the two groups, predominated 
by Streptococcus and Prevotella. When the authors evaluated the bacterial-fungal relationships in this 
dataset, they identified a number of significant correlations, including a significant negative 
correlation between the abundance of Rothia and Cladosporium in the oral cavity of healthy 
individuals, although no mechanistic justification for this correlation has been given. Interestingly, 
the authors go on to identify an antagonistic effect between the oral fungal genera Candidia and Pichia, 
such that a relative increase in Pichia colonisation was associated with a reduction in the abundance 
of Candida [26]. Highlighting the importance for elucidating the role of bacterial-fungal and fungal-
fungal interactions on microbiome and mycobiome community structures as well as health and 
disease.  
2.2.2. The Gut Mycobiome 
Perhaps the most widely studied fungal niche in humans is the gastrointestinal tract. The higher 
burden of fungal cells in the gut compared to other body niches, along with the wealth of data linking 
the gut microbiome to systemic inflammation makes the gut mycobiome an important area of study. 
Numerous authors have begun to unravel the role of the mycobiome in gut health [27], and disease, 
including; inflammatory bowel disease (IBD) [8,9,33], obesity [34], and inflammation [16,17,35]. 
Molecular studies of the gut mycobiome, have identified that healthy stools contain fungal 
genera belonging predominately to either the Ascomycota or Basidiomycota fungal taxa [27,33]. 
Furthermore, these studies report a rich and diverse fungal community within the GIT of healthy 
individuals which is predominated by Candida, Saccharomyces, Trichosporon and Cladosporium 
[16,27,36].  
In 2016, Mar Rodriguez et al. [34], investigated the role of the gut mycobiome in obesity, and 
showed that although there was no significant difference in mycobiome richness between obese and 
non-obese individuals, the specific composition of the mycobiome could distinguish between obese 
and non-obese individuals. In this respect, the obese mycobiome, was predominated by Candida, 
Nakaeseomyces, Penicillium and Pichia, whilst in the non-obese mycobiome Mucor, Candida and 
Penicillium were the most prevalent. Interestingly, the authors showed that the genus Mucor 
correlated negatively with metabolic markers of obesity (fasting triglycerides, low-density 
lipoprotein (LDL), cholesterol, BodyMass Index (BMI) and fat mass), whilst the genus Penicillium and 
the family Aspergillaceae correlated positively with high-density lipoprotein (HDL) [34]. Although, 
this study did not elucidate the role of the diet in obesity and mycobiome composition, a previous 
study by Hoffmann et al. [27] uncovered interactions between diet and the gut mycobiome. In that 
study Hoffmann et al. concurrently profiled the mycobiome and microbiome in stools (Figure 1), and 
showed that a healthy gut mycobiome is predominated by the fungal genera Candida and 
Saccharomyces, and the gut microbiome by Bacteroidetes and Firmicutes taxa. Of particular interest 
here were the positive associations of Candida with a carbohydrate-rich diet, and its co-occurrence 
with particular bacterial (Prevotella and Rumminococcus) and archaeal genera (Methanobrevibacter).  
Taken together, this data provides strong support for the role of bacterial-bacterial and fungal-
bacterial interactions in host metabolism, and systemic inflammatory conditions.  
A number of studies have begun to untangle the relationship between intestinal mycobiota and 
IBD [8,9,33]. In these studies, the gut mycobiome of patients with IBD is characterized by a reduction 
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in fungal biodiversity and a change in community composition compared to healthy controls. More 
specifically, at the phyla level, the ratio of fungi belonging to the Basidiomycota and Ascomycota taxa 
has been shown to be altered when compared to healthy controls, such that there is a statistically 
significant increase in Basidiomycota taxa at the expenses of Ascomycota seen in IBD [8]. The 
hallmarks of this dysbiosis appear to develop from a reduction in the relative abundance of 
Saccharomyces, Penicillium and Kluyveromyces coupled with an increase in Candida, Malasseziales and 
Filobasidiaceae in IBD compared to healthy controls [8]. Interestingly although both these studies 
reported a decrease in Saccharomyces cerevisiae and increase in Candida in stools from IBD cases, the 
exact species of Candida differed between the studies: Sokol reported an increase in C. albicans [8], 
whilst Hoarau reported an increase in Candida tropicalis [9]. These differences might be explained by 
the different extraction methodologies used, but this variation is most likely explained by the 
different ITS sequencing targets used in the two studies. Where the Sokol study targeted ITS2 and 
the Hoarau study targeted ITS1 [8,9]. 
3. Fungal Interactions 
When thinking about the role that a specific species, or the fungal community as a whole, may 
play in host health and disease, it is important to remember that these species and communities do 
not exist in isolation. Recent developments suggest that although the microbiome and mycobiome 
impact on the host they also affect each other, and the host will also impact on the homeostasis of 
these species through the production of metabolites and other, more specific factors and interactions.  
3.1. Polymicrobial Interactions and the Microbiome 
Although there are a significant number of studies exploring the bacterial communities, the 
importance of communities of fungal species in regulating the composition of the microbiome as a 
whole is only now beginning to be explored. In particular, the role of metabolites in these interactions 
is finally beginning to be explored [37]. The microbiota forms a complex ecosystem of cooperating 
microbes. Within this ecosystem each species will be producing metabolic intermediates, signalling 
molecules and toxins that will accumulate and impact on the physiology of other members of the 
community. Metabolic approaches confirm that growth within a polymicrobial community results in 
alterations to the global metabolome that are dependent on the species present in the community. 
These polymicrobial communities also result in the production of new secondary metabolites as a 
result of the action of multiple species in a chain of events, which may offer clinical significance. For 
example, mixed communities of Cladosporium and B. subtillis resulted in the production of a novel 
secondary metabolite that displayed antimicrobial properties, as well as an increase in surfactins [38]. 
Co-culturing Rhizopus microspores with Burkholderia gladioli also induces the production of 
bongkrekic acid—a notable respiratory toxin [39]. Therefore, although in their infancy, these types of 
studies provide evidence that polymicrobial communities (like those found in the microbiome) affect 
secondary metabolite production, which may affect the community structure as well as its 
interactions with the host habitat. For example, the presence of C. albicans in oral biofilms promotes 
the growth of S. mutans through the induction of genes involved in metabolic pathways [40]. The 
close-knit community of the microbiome, in conjunction with alterations in metabolic flux, will also 
set up micro-domains of differing environmental parameters (i.e., pH and H2O2) within the biofilm, 
driving shifts in the local communities [41]. These changes in environmental stimuli will change the 
community composition of the microbiome, with less fit organisms being outcompeted by microbes 
better suited to these conditions. Alternative ways fungal-bacterial interactions can affect the 
community structure include spatial rearrangements. It is now widely accepted that many bacteria 
adhere to fungal hyphae [42]. This attachment permits redistribution of bacteria within the discrete 
layers of medically important biofilms. There is also increasing evidence that the presence of fungi in 
multi-species communities promotes antimicrobial resistance. This reduced susceptibility to 
antibiotics appears to be mediated via fungal contributions to the extracellular matrix [43]. Therefore, 
although our current knowledge of the role of the interactions between fungi and bacteria on the 
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microbiota structure and composition are limited, there is precedent that these interactions play an 
important role and require further investigation. 
3.2. Fungal–Bacterial Interactions 
Fungi and bacteria can interact on multiple levels making polymicrobial interaction studies 
complex. These interactions can either be agonistic or antagonistic. The most studied fungal-bacterial 
interactions are those between C. albicans and Pseudomonas aeruginosa due to their co-habitation of 
and medical significance in the cystic fibrosis lung, and burns wounds. In this system, these two 
opportunistic pathogens display an antagonistic relationship. P. aeruginosa secretes 3-oxo C12 
homoserine lactone to control C. albicans morphogenesis, resulting in restricted hyphal growth [44]. 
However, quorum sensing only inhibits the initiation of hyphal formation, and does not affect 
extension of pre-existing hyphae [45]. To overcome this, P. aeruginosa has also evolved the ability to 
bind specifically to C. albicans hyphae through attachment to carbohydrate components of the fungal 
cell wall, and induce hyphal death [42]. P. aeruginosa also secretes phenazines (i.e., pyrocyanin) that 
are toxic to fungi [46]. While high concentrations of phenazines kill C. albicans, physiological 
concentrations permit growth on fermentable carbon sources, but restrict hyphal development [47]. 
The production of fermented by-products further enhances P. aeruginosa phenazine production, 
which promotes the colonisation of P. aeruginosa in the lung [48]. Therefore, P. aeruginosa appears to 
have evolved several mechanisms to manipulate C. albicans and restrict its growth to yeast. On one 
hand, this may seem counterproductive, as in other ecosystems bacteria use fungal hyphae to increase 
their dispersion, suggesting that P. aeruginosa could have evolved the ability to attach to C. albicans 
hyphae to aid its dissemination. Conversely, it is possible that yeast cells are better producers of 
fermented products than hyphae, which is why P. aeruginosa invests significant energy into 
maintaining C. albicans in its yeast form to promote its own colonisation in the host. However, C. 
albicans is not a silent partner in this relationship. C. albicans secretes its own quorum-sensing 
molecule, farnesol, which downregulates the expression of P. aeruginosa virulence factors through 
modulation of the Pseudomonas Quinolone System (PQS) system [49]. The roles these interactions 
play during infection are still unclear, and it is possible that the host environment determines which 
interactions will prevail.  
The best-documented agonistic fungal-bacterial interactions occur in the oral cavity during the 
formation of dental plaque. Binding of Streptococcus gordonii or Streptococcus mutans to C. albicans 
hyphae results in stable biofilm formation around the surface of the tooth. Binding is mediated via 
the bacterial surface proteins, CshA, SspA and SspB [50], and the fungal adhesin Als3 [51]. Despite 
colonising the hyphae, S. gordonii do not kill the hyphae. Instead, S. gordonii promotes C. albicans 
hyphal development through the secretion of the auto inducing peptide AI-2, and through the 
inhibition of farnesol repression [52]. However, other quorum sensing molecules secreted by S. 
gordonii and S. mutans can exert opposing effects on C. albicans morphogenesis, with diffusible signal 
factor (DFS) and competence stimulating peptide (CSP) both inhibiting hyphal formation [53,54]. 
Therefore, like the interactions between P. aeruginosa and C. albicans, the outcome of the interaction 
between S. gordonii and C. albicans is likely to be controlled by the local environment.  
3.3. Fungal–Fungal Interactions 
In addition to interacting with bacteria, fungi also interact with one another. For example, C. 
glabrata is able to bind to C. albicans hyphae and hitchhike [55] through the host. This attachment 
promotes invasion of C. glabrata into the oral mucosa and may enhance disseminated C. glabrata 
infections. This discovery has cause for concern as C. glabrata is inherently resistant the azole class of 
antifungals [56], the first drug of choice, making disseminated infection hard to treat.  
The quorum-sensing molecule, farnesol, secreted by C. albicans, is also able to control the 
morphology of other fungi inhibiting hyphal growth, conidiation and germination [57,58]. Although 
the complete mode of action of farnesol is not known, intracellular cAMP levels are reduced upon 
treatment with exogenous farnesol in many fungi [57], suggesting that inhibition of cAMP signalling 
pathways is a general trait of farnesol. In addition to inhibiting fungal morphogenesis, farnesol also 
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displays antifungal properties. For example, farnesol induces cell death in multiple fungal species via 
the generation of reactive oxygen species (ROS) from the mitochondria [59–61]. At high concentrations 
farnesol also induces apoptosis in C. albicans, which is dependent on ROS generation [62]. Therefore, C. 
albicans uses farnesol in antagonistic relationships with other fungi to reduce competition in the host, 
and to control its own growth and morphology by eliciting different responses to specific threshold 
concentrations of farnesol.  
3.4. Host-Fungal Interactions 
Alongside the potential for extensive exchanges between different members of the microbial 
communities and their concomitant impact, these communities will also interact with cells and 
systems of the host habitat. Whilst a key component of these interactions are those between the fungi 
and the host innate and adaptive immune system, the specifics of these interactions are covered 
elsewhere in this special issue. Thus, here, we will focus on the non-immune interactions between 
host and mycobiome.  
One of the more intriguing phenomena that may result from colonization by the mycobiome is 
“training” of the innate immune system. Recent studies have indicated that pre-exposure of 
macrophages to fungal cell wall products (β-glucan) results in epigenetic changes that ultimately lead 
to a stronger response on infection with live fungi at a later date [63]. Thus, the presence of a 
mycobiome may result in stronger innate protective responses to all microbes. Whether there is any 
specificity of this response to key species remains to be determined. 
As well as the mycobiome impacting on the host, the host can also have a significant impact on 
the mycobiome. The presence of microbes and their metabolites (such as short-chain fatty acids) leads 
to the production of a cocktail antimicrobial peptides (AMPs) that in turn can regulate the species 
present in the gut. The impact that this circuit can have on the microbiota and health is clearly 
demonstrated by work investigating the role of NLRP6 in colonic epithelial cells on health [64,65]. 
This work demonstrates that loss of a detection mechanism can lead to shifts in the microbiota and 
associated metabolome that can then impact on microbiome composition. Importantly, these shifts 
are maintained in an otherwise normal genetic background host due to the shift in metabolome. From 
this, we can see that an ability to model the interactions between host, mycobiome and metabolome 
will be extremely powerful tool in determining the role of host-mycobiome interactions in both health 
and disease. 
4. Modeling of the Mycobiome, Microbiome and Host Interactions 
Metagenomic analysis can provide information for the genes and species of the bacteria and 
potentially fungi, and through using different functional databases such as KEGG, the metabolic 
functions of these communities can be determined. However, due to the extreme complexity of 
human microbial ecosystems, multi-omics analyses are incapable of dissecting the overall 
metabolism of these ecosystems from community-level to individual level and thus elucidating the 
interactions between microbial species/strains, microbe and host, and other environmental factors. In 
the study of these complex biological ecosystems, mathematical modeling can provide critical 
insights that will assist in understanding the underlying mechanisms of these complex systems 
through the evaluation and testing of different hypothesis. Among these mathematical models, 
genome-scale metabolic models (GEMs) are perhaps the most important, and have been used to 
understand the molecular mechanisms of individual organisms in a biological system through the 
analysis of genotype-phenotype relationships [66]. Tissue/cell specific GEMs have been successfully 
applied to both human health and disease, to identify novel biomarkers for early diagnosis and 
efficient treatment of a variety of conditions, such as non-alcoholic fatty liver disease and certain 
cancer cell-types [67,68]. GEMs have shown their worth and utility in the study of fungi, through 
prediction of their phenotype in taking up different substrates, the effects of gene knockouts and as 
a platform for network independent analyses to identify key metabolites and sub-networks [69,70]. 
Recently, these powerful tools have been applied to the study of microbial communities, such as 
human gut microbiome [69]. Using GEMs in community metabolic modeling can successfully predict 
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the contribution of individual species and interactions between them to the overall simplified 
community metabolism and elucidate the interactions between the bacteria [71,72]. Through the 
generation of comprehensive toolboxes for community modeling, such as CASINO (Community And 
Systems-level INteractive Optimization), and the use of GEMs for predominant bacteria in human 
gut, the alteration in the amino acid profile of both feces and serum in response to diet interventions 
can be simulated and validated [73]. These successful examples of metabolic modeling of human 
tissue/cell-lines, fungi, and microbiome communities pave the way for the application of these 
methods on mycobiome research, enabling us to better understand the interactions between fungi 
and bacteria, other fungi and their host habitat; this allows us to elucidate their role in different 
diseases, alongside their overall contributions in human host-microbial metabolism.  
5. Conclusions 
As we develop an improved understanding of the pivotal role played by microbial communities 
in health and disease, we also increase our appreciation for the key role played by fungal 
communities in these situations. These fungal communities unsurprisingly show significant variation 
between different body habitats and with changes in disease status. We are beginning to grasp the 
significant role that these variations play in host homeostatic responses and pathologies, although 
our understanding here is still very much in its infancy. As we develop an increasing understanding 
of how factors such as host and microbial responses impact on the mycobiome and, likewise, how 
the mycobiome affects other microbial communities and the host, so we will improve our ability to 
predict the significance of changes in the mycobiome on host status. As we move forward, the 
importance and significance of advanced in silico modeling techniques (such as GEMs) associated 
with systems biology will be of ever-increasing importance, enabling us to create even more complex 
predictions of the role of different species, cell types and metabolites, with the ultimate goal of being 
able to determine specific, personalized interventions that improve the health of an individual. 
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